🏷

Classifications

Harrison's Part

👪

Inheritance

1

X-linked recessive inheritance HP:0001419

FGS4 is inherited in an X-linked manner. In the original Italian family the CASK p.R28L variant cosegregated with the phenotype through an obligate carrier mother, with affected hemizygous males and clinically unaffected carrier females, behaving as X-linked recessive. De novo CASK variants also cause the FGS4 phenotype, as in the reported patient with a de novo splice-site variant.

X-linked recessive inheritance

Show evidence (3 references)

PMID:19200522 SUPPORT Human Clinical

"The identified missense mutation cosegregates with the phenotype in this family and is absent in 1000 control X chromosomes of the same ethnic origin."

Establishes X-linked cosegregation of the CASK p.R28L variant with the FGS4 phenotype in the mapped Xp11.4 family.

PMID:24278995 SUPPORT Human Clinical

"CASK disorders are inherited in an X-linked manner."

GeneReviews states the X-linked inheritance mode for the CASK disorder spectrum, which includes FGS4.

PMID:24278995 SUPPORT Human Clinical

"the chance of transmitting it in each pregnancy is 50%: males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will typically be asymptomatic"

GeneReviews gives the X-linked transmission risk from a carrier mother relevant to genetic counseling for FGS4: 50% per pregnancy, with affected males and typically asymptomatic carrier females.

?

Discussions and Knowledge Gaps

1

FGS4 is defined jointly by a molecular criterion (a hypomorphic CASK variant) and membership in the historical, genetically heterogeneous "FG syndrome" clinical label. With only two reported FGS4-causing CASK variants and a broad, overlapping CASK phenotypic continuum, is "FG syndrome 4" a discrete clinical entity or simply the mild, syndromic end of the CASK spectrum labelled with a legacy FGS name?

KNOWLEDGE GAP OPEN fgs4_nosological_boundary

Attached to

pathophysiology#CASK Hypomorphic Altered-Function Variant

Only two families define FGS4 in the literature (Piluso 2009; Dunn 2017), and both reports frame the phenotype as one end of a CASK continuum rather than a separable entity. GeneReviews collapses the FGS4 presentation into "XLID with or without nystagmus" caused by hypomorphic CASK variants. The nosological status therefore remains open: FGS4 may be better modeled as a labelled region of the CASK spectrum than as an independent disorder, which affects how phenotype frequencies and boundaries should be curated as more cases accrue.

Proposed experiments

CASK genotype-phenotype cohort delineating the FGS4 region of the spectrum

fgs4_cask_genotype_phenotype_cohort

Assemble a cohort of hemizygous males with hypomorphic CASK variants and systematically phenotype them for the FGS-associated features (intellectual disability, nystagmus/ocular anomalies, gastrointestinal hypomotility, feeding difficulties) alongside quantitative CASK protein levels, to test whether an "FGS4" cluster is distinguishable from the broader hypomorphic CASK phenotype.

Decision criterion

A statistically distinct clustering of features and protein levels would support FGS4 as a discrete entity; a smooth continuum would support modeling it as a labelled region of the CASK spectrum.

Show evidence (1 reference)

PMID:25886057 SUPPORT Human Clinical

"three phenotypic groups can be distinguished that represent a clinical continuum"

Frames the CASK-related phenotypes in males as a continuum, which is the basis for questioning whether FGS4 is a discrete entity or a region of that continuum.

⚙

Pathophysiology

4

CASK Hypomorphic Altered-Function Variant

FGS4 is caused by CASK variants that lie at the mild, hypomorphic end of the CASK allelic spectrum. Rather than abolishing CASK, these missense and splice variants leave CASK protein detectable while reducing its amount or altering its function. This distinguishes FGS4 from the hemizygous loss-of-function CASK variants that cause the far more severe MICPCH phenotype with severe intellectual disability and, in males, epileptic encephalopathy. The first reported FGS4 variant, p.R28L (c.83G>T), causes partial skipping of CASK exon 2 through disrupted recognition of an exonic splicing enhancer; the second, the de novo splice-site variant c.2521-2A>G, causes skipping of exon 26 and yields an aberrant guanylate kinase domain.

CASK hgnc:1497

Downstream

Disrupted CASK Synaptic Scaffolding Complex Reduced or altered CASK protein impairs assembly of the CASK-organized presynaptic scaffolding complexes, particularly where the variant damages a protein-interaction domain such as the guanylate kinase domain.

Show evidence (4 references)

PMID:19200522 SUPPORT Human Clinical

"We report here that a p.R28L (c.83G-->T) missense mutation in CASK causes FGS phenotype in an Italian family previously mapped to Xp11.4-p11.3 (FGS4)."

Identifies the first causative CASK variant for FGS4 and localizes it to the FGS4 locus at Xp11.4.

PMID:19200522 SUPPORT In Vitro

"we observed a partial skipping of the exon 2 of CASK, presumably a consequence of improper recognition of exonic splicing enhancers (ESEs) induced by the c.83G-->T transversion."

Establishes the altered-splicing / hypomorphic molecular consequence of the FGS4 p.R28L variant rather than a simple missense change.

PMID:25886057 SUPPORT Human Clinical

"syndromic/nonsyndromic mild to severe ID with or without nystagmus caused by CASK missense and splice mutations that leave the CASK protein intact but likely alter its function or reduce the amount of normal protein"

Places FGS4 within the mildest of three CASK phenotypic groups in males, defined by hypomorphic missense/splice variants that retain CASK protein.

+ 1 more reference

Disrupted CASK Synaptic Scaffolding Complex

CASK is a multidomain MAGUK (membrane-associated guanylate kinase) scaffolding protein highly expressed in the central nervous system and localized to synapses. It forms competing tripartite CASK/Mint1/Velis and CASK/Caskin1/Velis complexes that physically associate with the cytoplasmic tail of neurexin at presynaptic sites, assembling large signaling complexes that regulate neurotransmission. FGS4 variants reduce or alter CASK so that these scaffolding interactions are perturbed; the exon-26-skipping variant specifically yields an aberrant guanylate kinase domain predicted to degrade CASK binding to neuronal and ocular development partners.

neuron CL:0000540

synapse organization GO:0050808

scaffold/adaptor activity GO:0030674

Downstream

Impaired Neurodevelopment and Synaptic Function Perturbed CASK scaffolding of presynaptic signaling complexes impairs synapse formation and neurotransmission during brain development and differentiation.

Impaired CASK-FRMD7 Ocular-Motor Scaffolding Damage to the CASK guanylate kinase domain degrades its interaction with FRMD7, a determinant of ocular-motor development and a known congenital-nystagmus gene.

Show evidence (4 references)

PMID:19200522 SUPPORT Human Clinical

"CASK is a multidomain scaffold protein highly expressed in the central nervous system (CNS) with specific localization to the synapses, where it forms large signaling complexes regulating neurotransmission."

Describes the synaptic scaffolding role of CASK whose disruption underlies the FGS4 neurodevelopmental phenotype.

PMID:21763699 SUPPORT In Vitro

"CASK forms competing CASK/Mint1/Velis and CASK/Caskin1/Velis tripartite complexes that physically associate with the cytoplasmic tail of neurexin, a transmembrane protein enriched at presynaptic sites."

Defines the specific tripartite CASK scaffolding complexes at the presynaptic neurexin tail that the FGS4 variants perturb.

PMID:28139025 SUPPORT Human Clinical

"The predominant mutant transcripts contain an aberrant guanylate kinase domain and thus are predicted to degrade CASK's ability to interact with important neuronal and ocular development proteins, including FRMD7."

Links the FGS4 exon-26-skipping variant to a damaged CASK protein-interaction (guanylate kinase) domain, impairing scaffolding of neuronal and ocular partners.

+ 1 more reference

Impaired Neurodevelopment and Synaptic Function

CASK is a conserved scaffolding protein involved in brain development, synapse formation, and establishment of cell polarity. FGS4 variants alter the CASK expression profile during embryogenesis, brain development, and differentiation, impairing synaptic assembly and neurotransmission and producing the neurodevelopmental phenotype (developmental delay, intellectual disability, and associated behavioral and neurological features).

neuron CL:0000540

synapse assembly GO:0007416

Show evidence (2 references)

PMID:21763699 SUPPORT In Vitro

"Calcium/calmodulin-dependent serine protein kinase (CASK) is a conserved multi-domain scaffolding protein involved in brain development, synapse formation, and establishment of cell polarity."

Establishes the neurodevelopmental roles of CASK whose disruption produces the FGS4 phenotype.

PMID:19200522 SUPPORT Human Clinical

"We suggest that the observed phenotype is most likely a consequence of an altered CASK expression profile during embryogenesis, brain development, and differentiation."

States the authors' mechanistic conclusion that altered CASK expression during neurodevelopment underlies the FGS4 phenotype.

Impaired CASK-FRMD7 Ocular-Motor Scaffolding

CASK interacts with FRMD7, a FERM-domain protein required for normal ocular-motor development and a well-established cause of X-linked congenital (infantile) nystagmus. An FGS4 variant that damages the CASK guanylate kinase domain is predicted to degrade the CASK-FRMD7 interaction, providing a mechanistic basis for the congenital nystagmus seen in FGS4.

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"predicted to degrade CASK's ability to interact with important neuronal and ocular development proteins, including FRMD7."

Provides the predicted molecular link between the FGS4 CASK variant and impaired FRMD7-dependent ocular-motor development underlying nystagmus.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

8

Digestive 2

Gastroesophageal reflux HP:0002020

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"Our patient presented with developmental delay, nystagmus, and severe gastrointestinal and gastroesophageal complications."

Documents severe gastroesophageal complications in the reported FGS4 patient; PARTIAL because the abstract states "gastroesophageal complications" rather than specifically naming reflux.

Feeding difficulties HP:0011968

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"Mutations in CASK cause X-linked intellectual disability, microcephaly with pontine and cerebellar hypoplasia, optic atrophy, nystagmus, feeding difficulties, GI hypomotility, and seizures."

Lists feeding difficulties among CASK-mutation phenotypes; PARTIAL because it characterizes CASK disorders broadly rather than FGS4 alone.

Eye 1

Optic atrophy HP:0000648

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"Mutations in CASK cause X-linked intellectual disability, microcephaly with pontine and cerebellar hypoplasia, optic atrophy, nystagmus, feeding difficulties, GI hypomotility, and seizures."

Lists optic atrophy among the ocular features of the CASK-mutation spectrum; PARTIAL because it characterizes CASK disorders broadly rather than FGS4 alone.

Nervous System 3

Intellectual disability HP:0001249

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Males have mild-to-severe intellectual disability, with or without nystagmus and other ocular features."

GeneReviews describes intellectual disability as the core feature of the hypomorphic (FGS4) CASK phenotype in males.

Global developmental delay HP:0001263

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"Our patient presented with developmental delay, nystagmus, and severe gastrointestinal and gastroesophageal complications."

Documents developmental delay in the reported FGS4 patient.

Atypical behavior HP:0000708

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"language skills and IQ are within normal range, although visual-motor, motor development, behavior, and working memory were impaired."

Documents impaired behavior (and visual-motor/working-memory) in the reported FGS4 patient.

Other 2

Congenital nystagmus HP:0006934

Show evidence (2 references)

PMID:28139025 SUPPORT Human Clinical

"Our patient presented with developmental delay, nystagmus, and severe gastrointestinal and gastroesophageal complications."

Directly documents nystagmus as a presenting feature in the reported FGS4 patient with the de novo splice-site CASK variant.

PMID:24278995 SUPPORT Human Clinical

"X-linked intellectual disability (XLID) with or without nystagmus, generally associated with hypomorphic CASK pathogenic variants."

GeneReviews links nystagmus to the hypomorphic CASK phenotype that encompasses FGS4, noting its variable presence.

Gastrointestinal dysmotility HP:0002579

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"Our patient presented with developmental delay, nystagmus, and severe gastrointestinal and gastroesophageal complications."

Documents severe gastrointestinal dysmotility complications in the reported FGS4 patient.

🧬

Genetic Associations

1

CASK

Gene: CASK hgnc:1497 relationship_type: CAUSATIVE variant_origin: GERMLINE

X-linked recessive inheritance

Show evidence (2 references)

PMID:19200522 SUPPORT Human Clinical

"We report here that a p.R28L (c.83G-->T) missense mutation in CASK causes FGS phenotype in an Italian family previously mapped to Xp11.4-p11.3 (FGS4)."

Establishes CASK as the causative gene for FGS4 and localizes it to Xp11.4.

PMID:28139025 SUPPORT Human Clinical

"This is the second CASK mutation known to us as cause of FGS4."

Confirms a second, independent CASK variant causing FGS4, supporting CASK as the FGS4 gene.

🔬

Variants

2

CASK p.Arg28Leu (c.83G>T) Pathogenic

Gene: CASK hgnc:1497 single nucleotide variant

The first reported FGS4 variant: a familial missense change (c.83G>T, p.Arg28Leu) that cosegregates with the phenotype in an Italian family mapped to Xp11.4. Functionally it acts as a hypomorph by causing partial skipping of CASK exon 2 through disrupted recognition of an exonic splicing enhancer, rather than by altering protein structure per se.

Also known as: p.R28L c.83G>T

Show evidence (1 reference)

PMID:19200522 SUPPORT Human Clinical

"we observed a partial skipping of the exon 2 of CASK, presumably a consequence of improper recognition of exonic splicing enhancers (ESEs) induced by the c.83G-->T transversion."

Describes the c.83G>T (p.Arg28Leu) variant and its hypomorphic altered-splicing mechanism.

CASK c.2521-2A>G (exon 26 skipping) Pathogenic

Gene: CASK hgnc:1497

The second reported FGS4 variant: a de novo carboxyl-terminus splice-site change (c.2521-2A>G) causing skipping of exon 26 and a cryptic-splice-site 9-bp deletion, yielding in-frame deletions (p.Ala841_Lys843del and p.Ala841_Glu868del) and an aberrant guanylate kinase domain in the predominant mutant transcripts.

Also known as: c.2521-2A>G p.Ala841_Glu868del

Show evidence (1 reference)

PMID:28139025 SUPPORT Human Clinical

"The c.2521-2A>G splice mutation leads to skipping of exon 26 and a 9 base-pair deletion associated with a cryptic splice site, leading to a 28-AA and a 3-AA in-frame deletion, respectively (p.Ala841_Lys843del and p.Ala841_Glu868del)."

Describes the second FGS4 variant and its exon-26-skipping molecular consequence.

💊

Medical Actions

3

Symptomatic developmental and intellectual-disability management

Category: Therapeutic Action: supportive care Ontology label: Supportive Care NCIT:C15747

Management of FGS4 is symptomatic and supportive, following standard care for developmental delay and intellectual disability, including educational and developmental services.

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."

GeneReviews specifies symptomatic management of developmental delay and intellectual disability for CASK disorders, including FGS4.

Nutritional support

Category: Therapeutic Action: nutritional support Ontology label: Nutritional Support NCIT:C15433

Nutritional support addresses the feeding difficulties and gastrointestinal hypomotility seen in the CASK spectrum, including FGS4.

Target Phenotypes: Feeding difficulties HP:0011968

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."

GeneReviews names nutritional support among the symptomatic treatments for CASK disorders.

Physiotherapy

Category: Therapeutic Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Physiotherapy supports motor development and mobility in CASK disorders including FGS4.

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"Treatment is symptomatic and includes standard management of developmental delay and intellectual disability issues; medication for seizures; nutritional support; use of physiotherapy; and treatment of abnormal vision or hearing loss."

GeneReviews names physiotherapy among the symptomatic treatments for CASK disorders.

🔬

Diagnosis

1

CASK molecular genetic testing

Diagnosis of FGS4 requires a compatible X-linked intellectual disability phenotype (with or without nystagmus) plus identification of a hemizygous hypomorphic CASK pathogenic variant in a male. Because the CASK phenotypic spectrum is broad and overlaps other X-linked intellectual disability disorders, testing is typically via a multigene intellectual disability panel containing CASK or exome/genome sequencing.

Show evidence (1 reference)

PMID:24278995 SUPPORT Human Clinical

"The diagnosis of a CASK disorder is established in a female who is heterozygous for a CASK pathogenic variant and in a male who is hemizygous for a CASK pathogenic variant on molecular genetic testing."

GeneReviews states the molecular diagnostic criterion for CASK disorders, including FGS4, in hemizygous males.

📊

Prevalence

1

Worldwide

Cases In Literature Not yet documented

No population prevalence or incidence has been established for FGS4 specifically. The molecular entity is known from only two published families/variants (Piluso et al. 2009, PMID:19200522; Dunn et al. 2017, PMID:28139025), so occurrence is recorded as not-yet-documented rather than estimated. Any broader CASK-disorder frequency figures pertain to the loss-of-function MICPCH end of the spectrum and must not be assigned to FGS4 (see notes and the fgs4_nosological_boundary discussion).

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from FG Syndrome 4:

CASK-related microcephaly with pontine and cerebellar hypoplasia (MICPCH)

Overlapping Features The severe end of the CASK allelic spectrum, caused by hemizygous CASK loss-of-function variants, presenting with progressive microcephaly, pontine and cerebellar hypoplasia, and severe intellectual disability, and in males frequently with epileptic encephalopathy. It is distinguished from FGS4 by its severity and by loss (rather than retention) of CASK protein.

Distinguishing Features

Loss-of-function CASK variant with no detectable CASK protein, versus retained protein in hypomorphic FGS4 variants
Progressive microcephaly with pontine and cerebellar hypoplasia
Severe-to-profound intellectual disability and, in males, epileptic encephalopathy

Show evidence (3 references)

PMID:25886057 SUPPORT Human Clinical

"MICPCH with severe epileptic encephalopathy caused by hemizygous loss-of-function mutations"

In this males-focused CASK cohort, hemizygous loss-of-function variants define the severe MICPCH-with-epileptic-encephalopathy end of the spectrum, contrasting with the hypomorphic FGS4 end.

PMID:25886057 SUPPORT In Vitro

"In fibroblasts from patients with a CASK loss-of-function mutation, no CASK protein could be detected"

Supports the loss (rather than retention) of CASK protein that distinguishes MICPCH loss-of-function variants from hypomorphic FGS4 variants. Immunoblot of cultured patient-derived fibroblasts (an ex vivo cellular assay), hence IN_VITRO.

PMID:25886057 SUPPORT In Vitro

"Individuals who are mosaic for a severe CASK mutation or carry a hypomorphic mutation still showed detectable amount of protein"

Backs the FGS4 side of the retained-versus-absent-protein distinction: hypomorphic variants leave detectable CASK protein, unlike loss-of-function MICPCH.

FG syndrome 1 (Opitz-Kaveggia syndrome, MED12)

Overlapping Features The prototypical, molecularly defined FG syndrome caused by the recurrent MED12 p.Arg961Trp variant at Xq13. It shares the historical "FG syndrome" clinical label and X-linked intellectual disability but is a distinct gene and locus; the older clinical "FG syndrome" umbrella is genetically heterogeneous across FGS1-5.

Distinguishing Features

Caused by MED12 (Xq13), not CASK (Xp11.4)
Distinctive Opitz-Kaveggia facial gestalt with relative macrocephaly, anal anomalies, and broad thumbs/halluces

Show evidence (1 reference)

PMID:19200522 SUPPORT Human Clinical

"Five loci (FGS1-5) have so far been linked to this phenotype on the X chromosome, but only one gene, MED12, has been identified to date."

Establishes that FG syndrome is genetically heterogeneous across five X-linked loci and distinguishes the MED12 (FGS1) entity from the CASK (FGS4) entity.

{ }

Source YAML

click to show

name: FG Syndrome 4
creation_date: "2026-08-05T00:00:00Z"
category: Mendelian
description: >-
  FG syndrome 4 (FGS4) is a rare X-linked intellectual disability / multiple congenital
  anomaly disorder caused by hypomorphic, altered-function variants in CASK
  (calcium/calmodulin-dependent serine protein kinase) at Xp11.4. It is the mildest end
  of the CASK allelic spectrum in males: whereas hemizygous loss-of-function CASK
  variants cause severe microcephaly with pontine and cerebellar hypoplasia (MICPCH),
  the missense and splice variants underlying FGS4 leave CASK protein detectable but
  reduce its amount or alter its function. Affected hemizygous males present with
  developmental delay and mild-to-severe intellectual disability, with or without
  congenital nystagmus and other ocular features, together with feeding difficulties and
  gastrointestinal hypomotility, in the historical clinical tradition of "FG syndrome"
  (an X-linked multiple congenital anomaly / intellectual disability phenotype first
  described in 1974 and later shown to be genetically heterogeneous across five X-linked
  loci, FGS1-5). CASK is a multidomain MAGUK scaffolding protein highly expressed in the
  central nervous system that organizes presynaptic signaling complexes on the
  cytoplasmic tail of neurexin; FGS4 variants perturb this scaffolding role during brain
  development and differentiation. Only two FGS4-causing CASK variants have been reported
  to date.
disease_term:
  preferred_term: FG syndrome 4
  term:
    id: MONDO:0010318
    label: FG syndrome 4
synonyms:
- FG syndrome type 4
- FGS4
- CASK FG syndrome
- CASK-related FG syndrome
parents:
- hereditary disease
- syndromic intellectual disability
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: NEUROLOGIC
references:
- reference: PMID:24278995
  title: "CASK Disorders."
  tags:
  - GeneReviews
  findings:
  - statement: >-
      Authoritative GeneReviews chapter covering the CASK disorder spectrum in both
      sexes: MICPCH associated with loss-of-function variants, and X-linked
      intellectual disability with or without nystagmus associated with hypomorphic
      variants (the FGS4 category in males), including diagnosis/testing, management,
      and X-linked genetic counseling.
inheritance:
- name: X-linked recessive inheritance
  description: >-
    FGS4 is inherited in an X-linked manner. In the original Italian family the CASK
    p.R28L variant cosegregated with the phenotype through an obligate carrier mother,
    with affected hemizygous males and clinically unaffected carrier females, behaving
    as X-linked recessive. De novo CASK variants also cause the FGS4 phenotype, as in
    the reported patient with a de novo splice-site variant.
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The identified missense mutation cosegregates with the phenotype in this family
      and is absent in 1000 control X chromosomes of the same ethnic origin.
    explanation: >-
      Establishes X-linked cosegregation of the CASK p.R28L variant with the FGS4
      phenotype in the mapped Xp11.4 family.
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CASK disorders are inherited in an X-linked manner.
    explanation: >-
      GeneReviews states the X-linked inheritance mode for the CASK disorder spectrum,
      which includes FGS4.
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the chance of transmitting it in each pregnancy is 50%: males who inherit the
      pathogenic variant will be affected; females who inherit the pathogenic variant
      will typically be asymptomatic
    explanation: >-
      GeneReviews gives the X-linked transmission risk from a carrier mother relevant to
      genetic counseling for FGS4: 50% per pregnancy, with affected males and typically
      asymptomatic carrier females.
pathophysiology:
- name: CASK Hypomorphic Altered-Function Variant
  biological_scale: MOLECULAR
  description: >-
    FGS4 is caused by CASK variants that lie at the mild, hypomorphic end of the CASK
    allelic spectrum. Rather than abolishing CASK, these missense and splice variants
    leave CASK protein detectable while reducing its amount or altering its function.
    This distinguishes FGS4 from the hemizygous loss-of-function CASK variants that
    cause the far more severe MICPCH phenotype with severe intellectual disability and,
    in males, epileptic encephalopathy. The first reported FGS4 variant, p.R28L
    (c.83G>T), causes partial skipping of CASK exon 2 through disrupted recognition of
    an exonic splicing enhancer; the second, the de novo splice-site variant
    c.2521-2A>G, causes skipping of exon 26 and yields an aberrant guanylate kinase
    domain.
  mechanism_confidence: ESTABLISHED
  gene:
    preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  evidence:
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report here that a p.R28L (c.83G-->T) missense mutation in CASK causes FGS
      phenotype in an Italian family previously mapped to Xp11.4-p11.3 (FGS4).
    explanation: >-
      Identifies the first causative CASK variant for FGS4 and localizes it to the
      FGS4 locus at Xp11.4.
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we observed a partial skipping of the exon 2 of CASK, presumably a consequence of
      improper recognition of exonic splicing enhancers (ESEs) induced by the c.83G-->T
      transversion.
    explanation: >-
      Establishes the altered-splicing / hypomorphic molecular consequence of the FGS4
      p.R28L variant rather than a simple missense change.
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      syndromic/nonsyndromic mild to severe ID with or without nystagmus caused by CASK
      missense and splice mutations that leave the CASK protein intact but likely alter
      its function or reduce the amount of normal protein
    explanation: >-
      Places FGS4 within the mildest of three CASK phenotypic groups in males, defined
      by hypomorphic missense/splice variants that retain CASK protein.
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Individuals who are mosaic for a severe CASK mutation or carry a hypomorphic
      mutation still showed detectable amount of protein.
    explanation: >-
      Confirms that hypomorphic CASK variants (the FGS4 class) retain detectable CASK
      protein, in contrast to the loss-of-function variants causing MICPCH.
  downstream:
  - target: Disrupted CASK Synaptic Scaffolding Complex
    causal_link_type: DIRECT
    description: >-
      Reduced or altered CASK protein impairs assembly of the CASK-organized presynaptic
      scaffolding complexes, particularly where the variant damages a protein-interaction
      domain such as the guanylate kinase domain.
- name: Disrupted CASK Synaptic Scaffolding Complex
  biological_scale: MOLECULAR
  description: >-
    CASK is a multidomain MAGUK (membrane-associated guanylate kinase) scaffolding
    protein highly expressed in the central nervous system and localized to synapses. It
    forms competing tripartite CASK/Mint1/Velis and CASK/Caskin1/Velis complexes that
    physically associate with the cytoplasmic tail of neurexin at presynaptic sites,
    assembling large signaling complexes that regulate neurotransmission. FGS4 variants
    reduce or alter CASK so that these scaffolding interactions are perturbed; the
    exon-26-skipping variant specifically yields an aberrant guanylate kinase domain
    predicted to degrade CASK binding to neuronal and ocular development partners.
  mechanism_confidence: ESTABLISHED
  molecular_functions:
  - preferred_term: scaffold/adaptor activity
    term:
      id: GO:0030674
      label: protein-macromolecule adaptor activity
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CASK is a multidomain scaffold protein highly expressed in the central nervous
      system (CNS) with specific localization to the synapses, where it forms large
      signaling complexes regulating neurotransmission.
    explanation: >-
      Describes the synaptic scaffolding role of CASK whose disruption underlies the
      FGS4 neurodevelopmental phenotype.
  - reference: PMID:21763699
    reference_title: "The molecular basis of the Caskin1 and Mint1 interaction with CASK."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      CASK forms competing CASK/Mint1/Velis and CASK/Caskin1/Velis tripartite complexes
      that physically associate with the cytoplasmic tail of neurexin, a transmembrane
      protein enriched at presynaptic sites.
    explanation: >-
      Defines the specific tripartite CASK scaffolding complexes at the presynaptic
      neurexin tail that the FGS4 variants perturb.
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The predominant mutant transcripts contain an aberrant guanylate kinase domain
      and thus are predicted to degrade CASK's ability to interact with important
      neuronal and ocular development proteins, including FRMD7.
    explanation: >-
      Links the FGS4 exon-26-skipping variant to a damaged CASK protein-interaction
      (guanylate kinase) domain, impairing scaffolding of neuronal and ocular partners.
  - reference: PMID:33090494
    reference_title: "Missense mutations in CASK, coding for the calcium-/calmodulin-dependent serine protein kinase, interfere with neurexin binding and neurexin-induced oligomerization."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      A total of five mutations in GK as well as PSD-95/discs large/ZO-1 (PDZ) domains
      affect binding of CASK to the pre-synaptic cell adhesion molecule Neurexin.
    explanation: >-
      Provides direct experimental evidence that CASK guanylate-kinase-domain mutations
      (the domain disrupted by the FGS4 exon-26-skipping variant) impair binding to the
      presynaptic scaffolding partner neurexin.
  downstream:
  - target: Impaired Neurodevelopment and Synaptic Function
    causal_link_type: DIRECT
    description: >-
      Perturbed CASK scaffolding of presynaptic signaling complexes impairs synapse
      formation and neurotransmission during brain development and differentiation.
  - target: Impaired CASK-FRMD7 Ocular-Motor Scaffolding
    causal_link_type: DIRECT
    description: >-
      Damage to the CASK guanylate kinase domain degrades its interaction with FRMD7,
      a determinant of ocular-motor development and a known congenital-nystagmus gene.
- name: Impaired Neurodevelopment and Synaptic Function
  biological_scale: CELLULAR
  description: >-
    CASK is a conserved scaffolding protein involved in brain development, synapse
    formation, and establishment of cell polarity. FGS4 variants alter the CASK
    expression profile during embryogenesis, brain development, and differentiation,
    impairing synaptic assembly and neurotransmission and producing the
    neurodevelopmental phenotype (developmental delay, intellectual disability, and
    associated behavioral and neurological features).
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: synapse assembly
    term:
      id: GO:0007416
      label: synapse assembly
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:21763699
    reference_title: "The molecular basis of the Caskin1 and Mint1 interaction with CASK."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Calcium/calmodulin-dependent serine protein kinase (CASK) is a conserved
      multi-domain scaffolding protein involved in brain development, synapse formation,
      and establishment of cell polarity.
    explanation: >-
      Establishes the neurodevelopmental roles of CASK whose disruption produces the
      FGS4 phenotype.
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We suggest that the observed phenotype is most likely a consequence of an altered
      CASK expression profile during embryogenesis, brain development, and
      differentiation.
    explanation: >-
      States the authors' mechanistic conclusion that altered CASK expression during
      neurodevelopment underlies the FGS4 phenotype.
- name: Impaired CASK-FRMD7 Ocular-Motor Scaffolding
  biological_scale: MOLECULAR
  description: >-
    CASK interacts with FRMD7, a FERM-domain protein required for normal ocular-motor
    development and a well-established cause of X-linked congenital (infantile) nystagmus.
    An FGS4 variant that damages the CASK guanylate kinase domain is predicted to degrade
    the CASK-FRMD7 interaction, providing a mechanistic basis for the congenital
    nystagmus seen in FGS4.
  mechanism_confidence: HYPOTHETICAL
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      predicted to degrade CASK's ability to interact with important neuronal and ocular
      development proteins, including FRMD7.
    explanation: >-
      Provides the predicted molecular link between the FGS4 CASK variant and impaired
      FRMD7-dependent ocular-motor development underlying nystagmus.
phenotypes:
- category: Neurologic
  name: Intellectual disability
  description: >-
    Hemizygous males with hypomorphic CASK variants (the FGS4 category) have
    mild-to-severe intellectual disability. Severity is variable across the spectrum;
    the patient with the de novo splice-site FGS4 variant had IQ and language within the
    normal range but impaired visual-motor, motor, behavioral, and working-memory
    function.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Males have mild-to-severe intellectual disability, with or without nystagmus and
      other ocular features.
    explanation: >-
      GeneReviews describes intellectual disability as the core feature of the
      hypomorphic (FGS4) CASK phenotype in males.
- category: Neurologic
  name: Global developmental delay
  description: >-
    Developmental delay is a presenting feature of FGS4, reported in the patient with
    the de novo splice-site CASK variant.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient presented with developmental delay, nystagmus, and severe
      gastrointestinal and gastroesophageal complications.
    explanation: >-
      Documents developmental delay in the reported FGS4 patient.
- category: Ophthalmologic
  name: Congenital nystagmus
  description: >-
    Congenital nystagmus is a characteristic feature of the hypomorphic CASK phenotype
    and was a defining feature in the reported FGS4 patient with the de novo splice-site
    variant, mechanistically linked to impaired CASK-FRMD7 interaction. It is variably
    present ("with or without nystagmus") across the FGS4 spectrum.
  phenotype_term:
    preferred_term: Congenital nystagmus
    term:
      id: HP:0006934
      label: Congenital nystagmus
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient presented with developmental delay, nystagmus, and severe
      gastrointestinal and gastroesophageal complications.
    explanation: >-
      Directly documents nystagmus as a presenting feature in the reported FGS4 patient
      with the de novo splice-site CASK variant.
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      X-linked intellectual disability (XLID) with or without nystagmus, generally
      associated with hypomorphic CASK pathogenic variants.
    explanation: >-
      GeneReviews links nystagmus to the hypomorphic CASK phenotype that encompasses
      FGS4, noting its variable presence.
- category: Ophthalmologic
  name: Optic atrophy
  description: >-
    Optic atrophy and other ocular features are part of the CASK-mutation phenotypic
    spectrum that includes FGS4. Reported here with PARTIAL support because the cited
    statement describes the broader CASK spectrum rather than an FGS4-specific series.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in CASK cause X-linked intellectual disability, microcephaly with
      pontine and cerebellar hypoplasia, optic atrophy, nystagmus, feeding difficulties,
      GI hypomotility, and seizures.
    explanation: >-
      Lists optic atrophy among the ocular features of the CASK-mutation spectrum;
      PARTIAL because it characterizes CASK disorders broadly rather than FGS4 alone.
- category: Gastrointestinal
  name: Gastrointestinal dysmotility
  description: >-
    Gastrointestinal hypomotility is part of the CASK phenotype, and the reported FGS4
    patient had severe gastrointestinal and gastroesophageal complications.
  phenotype_term:
    preferred_term: Gastrointestinal dysmotility
    term:
      id: HP:0002579
      label: Gastrointestinal dysmotility
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient presented with developmental delay, nystagmus, and severe
      gastrointestinal and gastroesophageal complications.
    explanation: >-
      Documents severe gastrointestinal dysmotility complications in the reported FGS4
      patient.
- category: Gastrointestinal
  name: Gastroesophageal reflux
  description: >-
    Severe gastroesophageal complications were reported in the FGS4 patient with the de
    novo splice-site CASK variant.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient presented with developmental delay, nystagmus, and severe
      gastrointestinal and gastroesophageal complications.
    explanation: >-
      Documents severe gastroesophageal complications in the reported FGS4 patient;
      PARTIAL because the abstract states "gastroesophageal complications" rather than
      specifically naming reflux.
- category: Gastrointestinal
  name: Feeding difficulties
  description: >-
    Feeding difficulties are part of the CASK-mutation phenotypic spectrum encompassing
    FGS4. Reported with PARTIAL support as the citation describes the broader CASK
    spectrum.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in CASK cause X-linked intellectual disability, microcephaly with
      pontine and cerebellar hypoplasia, optic atrophy, nystagmus, feeding difficulties,
      GI hypomotility, and seizures.
    explanation: >-
      Lists feeding difficulties among CASK-mutation phenotypes; PARTIAL because it
      characterizes CASK disorders broadly rather than FGS4 alone.
- category: Behavioral
  name: Atypical behavior
  description: >-
    Behavioral function was impaired in the reported FGS4 patient, alongside impaired
    visual-motor, motor, and working-memory function, despite IQ and language in the
    normal range.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      language skills and IQ are within normal range, although visual-motor, motor
      development, behavior, and working memory were impaired.
    explanation: >-
      Documents impaired behavior (and visual-motor/working-memory) in the reported FGS4
      patient.
genetic:
- name: CASK
  notes: >-
    CASK (Xp11.4) encodes a calcium/calmodulin-dependent serine protein kinase of the
    MAGUK scaffold family. FGS4 is caused by hypomorphic CASK variants at the mild end
    of the allelic spectrum; only two have been reported: the familial missense
    p.R28L (c.83G>T), which causes partial skipping of exon 2, and the de novo
    splice-site variant c.2521-2A>G, which causes skipping of exon 26 and an aberrant
    guanylate kinase domain. Loss-of-function CASK variants instead cause MICPCH and
    should not be labelled FGS4.
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  inheritance:
  - name: X-linked recessive inheritance
    inheritance_term:
      preferred_term: X-linked recessive inheritance
      term:
        id: HP:0001419
        label: X-linked recessive inheritance
  evidence:
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report here that a p.R28L (c.83G-->T) missense mutation in CASK causes FGS
      phenotype in an Italian family previously mapped to Xp11.4-p11.3 (FGS4).
    explanation: >-
      Establishes CASK as the causative gene for FGS4 and localizes it to Xp11.4.
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is the second CASK mutation known to us as cause of FGS4.
    explanation: >-
      Confirms a second, independent CASK variant causing FGS4, supporting CASK as the
      FGS4 gene.
variants:
- name: CASK p.Arg28Leu (c.83G>T)
  description: >-
    The first reported FGS4 variant: a familial missense change (c.83G>T, p.Arg28Leu)
    that cosegregates with the phenotype in an Italian family mapped to Xp11.4.
    Functionally it acts as a hypomorph by causing partial skipping of CASK exon 2
    through disrupted recognition of an exonic splicing enhancer, rather than by
    altering protein structure per se.
  gene:
    preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  clinical_significance: PATHOGENIC
  type: single_nucleotide_variant
  synonyms:
  - p.R28L
  - c.83G>T
  evidence:
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we observed a partial skipping of the exon 2 of CASK, presumably a consequence of
      improper recognition of exonic splicing enhancers (ESEs) induced by the c.83G-->T
      transversion.
    explanation: >-
      Describes the c.83G>T (p.Arg28Leu) variant and its hypomorphic altered-splicing
      mechanism.
- name: CASK c.2521-2A>G (exon 26 skipping)
  description: >-
    The second reported FGS4 variant: a de novo carboxyl-terminus splice-site change
    (c.2521-2A>G) causing skipping of exon 26 and a cryptic-splice-site 9-bp deletion,
    yielding in-frame deletions (p.Ala841_Lys843del and p.Ala841_Glu868del) and an
    aberrant guanylate kinase domain in the predominant mutant transcripts.
  gene:
    preferred_term: CASK
    term:
      id: hgnc:1497
      label: CASK
  clinical_significance: PATHOGENIC
  synonyms:
  - c.2521-2A>G
  - p.Ala841_Glu868del
  evidence:
  - reference: PMID:28139025
    reference_title: "A de novo splice site mutation in CASK causes FG syndrome-4 and congenital nystagmus."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The c.2521-2A>G splice mutation leads to skipping of exon 26 and a 9 base-pair
      deletion associated with a cryptic splice site, leading to a 28-AA and a 3-AA
      in-frame deletion, respectively (p.Ala841_Lys843del and p.Ala841_Glu868del).
    explanation: >-
      Describes the second FGS4 variant and its exon-26-skipping molecular consequence.
diagnosis:
- name: CASK molecular genetic testing
  description: >-
    Diagnosis of FGS4 requires a compatible X-linked intellectual disability phenotype
    (with or without nystagmus) plus identification of a hemizygous hypomorphic CASK
    pathogenic variant in a male. Because the CASK phenotypic spectrum is broad and
    overlaps other X-linked intellectual disability disorders, testing is typically via
    a multigene intellectual disability panel containing CASK or exome/genome
    sequencing.
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of a CASK disorder is established in a female who is heterozygous
      for a CASK pathogenic variant and in a male who is hemizygous for a CASK
      pathogenic variant on molecular genetic testing.
    explanation: >-
      GeneReviews states the molecular diagnostic criterion for CASK disorders,
      including FGS4, in hemizygous males.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No population prevalence or incidence has been established for FGS4 specifically.
    The molecular entity is known from only two published families/variants (Piluso
    et al. 2009, PMID:19200522; Dunn et al. 2017, PMID:28139025), so occurrence is
    recorded as not-yet-documented rather than estimated. Any broader CASK-disorder
    frequency figures pertain to the loss-of-function MICPCH end of the spectrum and
    must not be assigned to FGS4 (see notes and the fgs4_nosological_boundary
    discussion).
differential_diagnoses:
- name: CASK-related microcephaly with pontine and cerebellar hypoplasia (MICPCH)
  description: >-
    The severe end of the CASK allelic spectrum, caused by hemizygous CASK
    loss-of-function variants, presenting with progressive microcephaly, pontine and
    cerebellar hypoplasia, and severe intellectual disability, and in males frequently
    with epileptic encephalopathy. It is distinguished from FGS4 by its severity and by
    loss (rather than retention) of CASK protein.
  distinguishing_features:
  - Loss-of-function CASK variant with no detectable CASK protein, versus retained
    protein in hypomorphic FGS4 variants
  - Progressive microcephaly with pontine and cerebellar hypoplasia
  - Severe-to-profound intellectual disability and, in males, epileptic encephalopathy
  evidence:
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MICPCH with severe epileptic encephalopathy caused by hemizygous
      loss-of-function mutations
    explanation: >-
      In this males-focused CASK cohort, hemizygous loss-of-function variants define
      the severe MICPCH-with-epileptic-encephalopathy end of the spectrum, contrasting
      with the hypomorphic FGS4 end.
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In fibroblasts from patients with a CASK loss-of-function mutation, no CASK
      protein could be detected
    explanation: >-
      Supports the loss (rather than retention) of CASK protein that distinguishes
      MICPCH loss-of-function variants from hypomorphic FGS4 variants. Immunoblot of
      cultured patient-derived fibroblasts (an ex vivo cellular assay), hence IN_VITRO.
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Individuals who are mosaic for a severe CASK mutation or carry a hypomorphic
      mutation still showed detectable amount of protein
    explanation: >-
      Backs the FGS4 side of the retained-versus-absent-protein distinction: hypomorphic
      variants leave detectable CASK protein, unlike loss-of-function MICPCH.
- name: FG syndrome 1 (Opitz-Kaveggia syndrome, MED12)
  description: >-
    The prototypical, molecularly defined FG syndrome caused by the recurrent MED12
    p.Arg961Trp variant at Xq13. It shares the historical "FG syndrome" clinical label
    and X-linked intellectual disability but is a distinct gene and locus; the older
    clinical "FG syndrome" umbrella is genetically heterogeneous across FGS1-5.
  distinguishing_features:
  - Caused by MED12 (Xq13), not CASK (Xp11.4)
  - Distinctive Opitz-Kaveggia facial gestalt with relative macrocephaly, anal
    anomalies, and broad thumbs/halluces
  evidence:
  - reference: PMID:19200522
    reference_title: "A missense mutation in CASK causes FG syndrome in an Italian family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Five loci (FGS1-5) have so far been linked to this phenotype on the X chromosome,
      but only one gene, MED12, has been identified to date.
    explanation: >-
      Establishes that FG syndrome is genetically heterogeneous across five X-linked
      loci and distinguishes the MED12 (FGS1) entity from the CASK (FGS4) entity.
treatments:
- name: Symptomatic developmental and intellectual-disability management
  description: >-
    Management of FGS4 is symptomatic and supportive, following standard care for
    developmental delay and intellectual disability, including educational and
    developmental services.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment is symptomatic and includes standard management of developmental delay
      and intellectual disability issues; medication for seizures; nutritional support;
      use of physiotherapy; and treatment of abnormal vision or hearing loss.
    explanation: >-
      GeneReviews specifies symptomatic management of developmental delay and
      intellectual disability for CASK disorders, including FGS4.
- name: Nutritional support
  description: >-
    Nutritional support addresses the feeding difficulties and gastrointestinal
    hypomotility seen in the CASK spectrum, including FGS4.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: nutritional support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment is symptomatic and includes standard management of developmental delay
      and intellectual disability issues; medication for seizures; nutritional support;
      use of physiotherapy; and treatment of abnormal vision or hearing loss.
    explanation: >-
      GeneReviews names nutritional support among the symptomatic treatments for CASK
      disorders.
- name: Physiotherapy
  description: >-
    Physiotherapy supports motor development and mobility in CASK disorders including
    FGS4.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:24278995
    reference_title: "CASK Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment is symptomatic and includes standard management of developmental delay
      and intellectual disability issues; medication for seizures; nutritional support;
      use of physiotherapy; and treatment of abnormal vision or hearing loss.
    explanation: >-
      GeneReviews names physiotherapy among the symptomatic treatments for CASK
      disorders.
discussions:
- discussion_id: fgs4_nosological_boundary
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    FGS4 is defined jointly by a molecular criterion (a hypomorphic CASK variant) and
    membership in the historical, genetically heterogeneous "FG syndrome" clinical
    label. With only two reported FGS4-causing CASK variants and a broad, overlapping
    CASK phenotypic continuum, is "FG syndrome 4" a discrete clinical entity or simply
    the mild, syndromic end of the CASK spectrum labelled with a legacy FGS name?
  attaches_to:
  - pathophysiology#CASK Hypomorphic Altered-Function Variant
  rationale: >-
    Only two families define FGS4 in the literature (Piluso 2009; Dunn 2017), and both
    reports frame the phenotype as one end of a CASK continuum rather than a separable
    entity. GeneReviews collapses the FGS4 presentation into "XLID with or without
    nystagmus" caused by hypomorphic CASK variants. The nosological status therefore
    remains open: FGS4 may be better modeled as a labelled region of the CASK spectrum
    than as an independent disorder, which affects how phenotype frequencies and
    boundaries should be curated as more cases accrue.
  proposed_experiments:
  - experiment_id: fgs4_cask_genotype_phenotype_cohort
    name: CASK genotype-phenotype cohort delineating the FGS4 region of the spectrum
    description: >-
      Assemble a cohort of hemizygous males with hypomorphic CASK variants and
      systematically phenotype them for the FGS-associated features (intellectual
      disability, nystagmus/ocular anomalies, gastrointestinal hypomotility, feeding
      difficulties) alongside quantitative CASK protein levels, to test whether an
      "FGS4" cluster is distinguishable from the broader hypomorphic CASK phenotype.
    decision_criterion: >-
      A statistically distinct clustering of features and protein levels would support
      FGS4 as a discrete entity; a smooth continuum would support modeling it as a
      labelled region of the CASK spectrum.
  evidence:
  - reference: PMID:25886057
    reference_title: "Phenotypic and molecular insights into CASK-related disorders in males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      three phenotypic groups can be distinguished that represent a clinical continuum
    explanation: >-
      Frames the CASK-related phenotypes in males as a continuum, which is the basis
      for questioning whether FGS4 is a discrete entity or a region of that continuum.
notes: >-
  FGS4 is one of five historically defined X-linked FG syndrome loci (FGS1-5). Among
  these, only MED12 (FGS1), FLNA (FGS2), and CASK (FGS4) have identified causative
  genes; the FGS3 and FGS5 loci remain gene-unidentified. UPF3B and BRWD3 are additional
  X-linked intellectual disability genes that have been implicated in families
  historically labelled with FG-like phenotypes, but they are not assigned standard
  FGS locus numbers in the FGS1-5 series. This entry is scoped strictly to the CASK-defined
  molecular entity MONDO:0010318 and should not be conflated with the historical,
  genetically heterogeneous clinical "FG syndrome" umbrella (MONDO:0002010). Because
  only two FGS4-causing CASK variants have been reported, phenotype frequencies are
  deliberately omitted rather than estimated from n=2. Seizures/epileptic encephalopathy
  are likewise deliberately not curated as FGS4 phenotypes: in the Moog (2015) males
  series they mark the severe hemizygous loss-of-function MICPCH end of the CASK spectrum
  (modeled here only as the MICPCH differential), not the hypomorphic FGS4 region, which
  is characterized by mild-to-severe ID with or without nystagmus.

📚

References & Deep Research

References

1

PMID:24278995

CASK Disorders.

1 finding

Authoritative GeneReviews chapter covering the CASK disorder spectrum in both sexes: MICPCH associated with loss-of-function variants, and X-linked intellectual disability with or without nystagmus associated with hypomorphic variants (the FGS4 category in males), including diagnosis/testing, management, and X-linked genetic counseling.

Deep Research

1

Falcon ▸

FG Syndrome 4: Disease Characteristics Research Report

Edison Scientific Literature 25 citations 2026-08-05T21:56:55.580867

FG Syndrome 4: Disease Characteristics Research Report

Scope and critical curation note. FG syndrome 4 (FGS4) is an exceptionally sparsely documented historical FG-syndrome subtype. Current disease databases map it to MONDO:0010318 and associate it with CASK. However, most modern clinical and mechanistic evidence concerns the broader spectrum of CASK-related disorders, not cohorts explicitly diagnosed as FGS4. Accordingly, this report labels evidence as either direct FGS4 evidence or broader CASK-spectrum evidence; frequencies from the latter should not be entered as FGS4-specific frequencies without qualification. Open Targets identifies CASK as the sole associated target, with an association score of 0.80 and predominantly genetic support. (OpenTargets Search: FG syndrome 4)

Table: This table condenses high-yield knowledge-base facts for FG syndrome 4, clearly separating direct FG syndrome 4 evidence from broader CASK-related disorder evidence. It is useful for curation because the disease-specific literature is sparse and much current understanding is inferred from the larger CASK clinical and mechanistic spectrum.

1. Disease information

Definition

FGS4 is a rare, Mendelian, X-linked syndromic neurodevelopmental disorder historically mapped to Xp11.4–p11.3 and now linked to pathogenic variation in CASK, encoding calcium/calmodulin-dependent serine protein kinase. The modern molecular interpretation places FGS4 within the broader CASK-related neurodevelopmental spectrum, which includes X-linked intellectual disability, congenital nystagmus, epilepsy, and microcephaly with pontine and cerebellar hypoplasia (MICPCH). (OpenTargets Search: FG syndrome 4, mori2023diverseclinicalphenotypes pages 1-2)

It must not be conflated with classic FG syndrome/FG syndrome 1, which is MED12-related. Historical FG-syndrome classification was phenotype based and genetically heterogeneous; consequently, older FGS labels do not always map cleanly to current molecular diagnoses.

Identifiers and synonyms

MONDO: MONDO:0010318.
Causal gene association: CASK, Ensembl ENSG00000147044, chromosome Xp11.4. (OpenTargets Search: FG syndrome 4)
Common names: FG syndrome 4; FGS4; FG syndrome type 4; CASK-related FG syndrome.
Broader—but not strictly synonymous—terms: CASK-related disorder; CASK-related intellectual disability; X-linked intellectual disability with or without nystagmus; MICPCH.
OMIM/Orphanet/MeSH/ICD-10/ICD-11: No independently verified FGS4-specific entries or codes were recovered in the retrieved evidence. Generic intellectual-disability, congenital-malformation, microcephaly, epilepsy, or pontocerebellar-hypoplasia codes may be used clinically, but they are not specific identifiers for FGS4.

The evidence summarized here is aggregated disease-level literature and database evidence, not individual EHR data. Some primary studies report individual patients or small cohorts.

2. Etiology

Causal factors and genetic risk

The primary cause is a germline pathogenic CASK variant. Reported CASK disease alleles across the broader spectrum include nonsense, frameshift, splice-site, missense, intragenic deletion/duplication, and larger Xp11.4 copy-number variants. Loss-of-function alleles generally reduce or eliminate functional protein; missense alleles may be hypomorphic or selectively disrupt particular molecular interactions. (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)

In a 2017 study of 41 patients selected for intellectual disability and MICPCH, 32 had CASK abnormalities—23 point variants and nine copy-number variants. The paper reports a 90.2% overall molecular identification rate, including non-CASK candidate diagnoses, rather than a 90.2% CASK rate. Parental testing showed that all assessed variants except one were de novo. (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 2-3)

Sex and X-chromosome constitution strongly influence severity. Hemizygous males have all cells exposed to the variant and severe null alleles may be perinatal lethal. Heterozygous females are mosaics through X-chromosome inactivation and often survive with variable disease. Somatic mosaicism can attenuate disease in males. (mukherjee2022thenonlinearpath pages 3-5, mori2023diverseclinicalphenotypes pages 5-7)

Environmental, lifestyle, infectious, and protective factors

No reproducible environmental toxin, infection, diet, lifestyle exposure, or occupational factor is known to cause or materially modify FGS4. No validated protective CASK allele, modifier gene, protective exposure, or gene–environment interaction was identified. Family history is relevant only through inheritance or parental germline/somatic mosaicism. These negative findings are consistent with a highly penetrant Mendelian developmental disorder, but formal gene–environment studies are lacking.

3. Phenotypes

Direct FGS4 frequency data are unavailable. The following estimates derive from aggregated CASK-related disorder literature and should be curated with that qualifier.

Intellectual disability/global developmental delay: 96.1% of males and 93.5% of females in the 2023 review. Severity ranges from mild to profound, but severe impairment predominates in MICPCH cohorts. Suggested HPO: Intellectual disability, Global developmental delay, Delayed speech and language development. (mori2023diverseclinicalphenotypes pages 5-7)
Microcephaly/MICPCH: 76.0% of males and 87.7% of females in the same review. Head growth may be normal or mildly reduced at birth and become progressively abnormal postnatally; prenatal onset is reported in some patients. Suggested HPO: Microcephaly, Progressive microcephaly, Pontocerebellar hypoplasia, Cerebellar hypoplasia, Pontine hypoplasia. (mori2023diverseclinicalphenotypes pages 5-7, mori2023diverseclinicalphenotypes pages 8-9)
Epilepsy: 54.1% of males versus 36.1% of females, a reported sex difference of p=0.0198. Onset and seizure type are variable; severe males may have early refractory epilepsy. Suggested HPO: Seizure, Epileptic encephalopathy, with seizure-subtype terms assigned case by case. (mukherjee2022thenonlinearpath pages 3-5, mori2023diverseclinicalphenotypes pages 5-7)
Motor impairment: hypotonia, dystonia, impaired coordination, delayed or absent walking, and sometimes later spasticity. In the 41-person MICPCH cohort, only 6 walked and 3 spoke, illustrating severe functional morbidity in an ascertainment-enriched cohort. Suggested HPO: Muscular hypotonia, Dystonia, Motor delay, Gait abnormality. (hayashi2017comprehensiveinvestigationof pages 2-3)
Ophthalmologic/oculomotor disease: congenital nystagmus, optic atrophy or optic-nerve hypoplasia, glaucoma, megalocornea, and cerebral visual impairment are reported. Nystagmus has incomplete penetrance and has been associated mechanistically with C-terminal CASK–FRMD7 interactions. Suggested HPO: Congenital nystagmus, Optic atrophy, Optic nerve hypoplasia, Glaucoma, Megalocornea. (mukherjee2022thenonlinearpath pages 3-5)
Hearing impairment: sensorineural hearing loss is recurrent. Suggested HPO: Sensorineural hearing impairment. (hayashi2017comprehensiveinvestigationof pages 2-3, martin2025theneurodevelopmentalspectrum pages 1-2)
Growth and musculoskeletal findings: growth retardation, scoliosis, and occasionally contractures or FG-like congenital anomalies. Suggested HPO: Growth delay, Scoliosis.
Behavioral/neuropsychiatric phenotype: autistic traits or autism-spectrum diagnoses and sleep difficulties occur in the broader CASK spectrum. Quantitative FGS4-specific data are unavailable. Suggested HPO: Autistic behavior, Sleep disturbance. (mori2023diverseclinicalphenotypes pages 1-2, martin2025theneurodevelopmentalspectrum pages 1-2)
Facial dysmorphism: generally mild and variable in CASK cohorts; historical FG-like gestalt is insufficient for molecular diagnosis.

Symptoms are congenital or begin in infancy/childhood. The condition is lifelong. Developmental disability is generally stable, while head-growth deceleration and cerebellar degeneration can be progressive. Epilepsy may be episodic or chronic. No validated FGS4-specific EQ-5D, SF-36, PROMIS, or other quality-of-life study was found; nevertheless, impaired communication, mobility, vision, hearing, feeding, and seizure burden can substantially limit daily functioning.

4. Genetic and molecular information

Gene and variants

CASK encodes an X-linked multidomain membrane-associated guanylate kinase-family protein. Its principal domains are an N-terminal atypical CaMK domain, two L27 domains, PDZ, SH3, and guanylate-kinase-like domains. (mukherjee2022thenonlinearpath pages 5-6, mori2023diverseclinicalphenotypes pages 1-2, tibbe2021functionalanalysisof pages 1-2)

Broader CASK studies support the following genotype–phenotype tendencies:

Nonsense and frameshift alleles usually cause loss of function and are overrepresented among affected females; severe constitutive null alleles are poorly tolerated in males.
Missense alleles can disrupt selected binding partners and may permit survival in males. Five experimentally studied variants were p.Arg489Trp, p.Met507Ile, p.Gly521Val, p.Asn798Tyr, and p.Val849Ala. (pan2021missensemutationsin pages 4-6)
Missense variants associated with intellectual disability and epilepsy occur throughout the protein, whereas variants associated with microcephaly/MICPCH appear more domain restricted. (mori2023diverseclinicalphenotypes pages 1-2)
Copy-number variants can remove part or all of CASK and sometimes neighboring genes, complicating attribution.

Variants are principally germline, although somatic mosaic variants occur. Population allele frequencies for individual FGS4 alleles were not recovered; fully penetrant severe variants are expected to be absent or extremely rare in population databases. No founder allele, anticipation, or established modifier gene is known. Female expression is influenced by X-inactivation, but no validated disease-specific methylation episignature was identified.

HGNC ID, ClinVar accessions, exact HGVS sequence for the reported FGS4 splice variant, and allele frequencies should be added only after direct ClinVar/HGNC transcript verification. They were not available in the retrieved full-text evidence and should not be inferred.

5. Environmental information

No causal environmental exposure, lifestyle factor, or infectious agent applies. Smoking, alcohol, diet, exercise, pollution, radiation, and occupational exposure have not been shown to determine disease occurrence. Maternal exposures could independently affect neurodevelopment but are not recognized causes of FGS4. CTD-like chemical–gene associations should not be promoted to disease-risk factors without human evidence.

6. Mechanism and pathophysiology

Upstream-to-downstream causal model

Pathogenic CASK variation causes haploinsufficiency, complete loss, or selective impairment of a functional domain.
Protein interaction and localization defects disturb CASK scaffolding at presynaptic and postsynaptic sites and in the nucleus/cytoplasm. Important partners include neurexin, liprin-α, Mint1, Veli/Lin7, SAP97, syndecan, SynCAM, TBR1, CINAP, FRMD7, and CNTNAP2. (mukherjee2022thenonlinearpath pages 8-9, mukherjee2022thenonlinearpath pages 6-8, tibbe2021functionalanalysisof pages 1-2)
Synaptic and transcriptional consequences include impaired neurexin binding and neurexin-induced CASK oligomerization, altered active-zone organization, NMDA/AMPA receptor trafficking, and altered TBR1-associated regulation of RELN and GRIN2B/NR2B. (mukherjee2022thenonlinearpath pages 5-6, pan2021missensemutationsin pages 4-6, pan2021missensemutationsin pages 9-11)
Network/cellular consequences include altered excitatory–inhibitory balance, impaired postnatal brain growth, and vulnerability of cerebellar granule cells. Heterozygous mouse proteomics found more than 500 differentially expressed proteins, including 99 mitochondrial proteins, supporting additional cytoskeletal, translational/chaperone, and metabolic components. (mukherjee2022thenonlinearpath pages 8-9)
Tissue-level effects include disproportionate hindbrain and cerebellar injury, optic-nerve hypoplasia, microcephaly, and—in severe males—brainstem dysfunction affecting respiration and swallowing. These produce developmental disability, ataxia/motor impairment, epilepsy, nystagmus, and sensory deficits. (mukherjee2022thenonlinearpath pages 3-5, mukherjee2022thenonlinearpath pages 8-9)

Important expert interpretation

A simple “loss of synaptic CASK function causes maldevelopment” model is inadequate. Cask-null mice can show largely normal initial brain lamination and synaptic ultrastructure, while heterozygous animals develop postnatal abnormalities. Cell-specific deletion from Purkinje cells, retinal ganglion cells, or granule-cell precursors does not independently reproduce degeneration. This supports non-cell-autonomous, tissue-level pathogenesis and later neurodegeneration rather than a pure neuronal migration defect. (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 5-6)

The 2022 review’s central caution is that CASK molecular functions and clinical pathology have a “highly complex relationship”; mechanistic annotations should therefore separate demonstrated interactions from proven disease-causal pathways. (mukherjee2022thenonlinearpath pages 6-8)

Ontology suggestions

GO biological process: synapse organization; regulation of synaptic vesicle exocytosis; receptor localization to synapse; regulation of transcription by RNA polymerase II; postnatal brain development; regulation of neuron death; regulation of mitochondrial metabolism.
GO molecular function: protein-domain-specific binding; scaffold protein binding; protein serine/threonine kinase activity; neurexin binding.
GO cellular component: presynaptic active zone; postsynaptic density; neuronal nucleus; cytosol; plasma membrane.
Cell Ontology labels: neuron; cerebellar granule cell; Purkinje cell; retinal ganglion cell; excitatory neuron; inhibitory neuron. Exact CL identifiers should be ontology-validated before ingestion.

No validated FGS4-specific single-cell, spatial-transcriptomic, lipidomic, or metabolomic signature was found. Human induced cortical excitatory-neuron models exist in the broader CASK field, but no clinical omics biomarker is established.

7. Anatomical structures affected

The central nervous system is primary, especially:

cerebellum, particularly the granule-cell layer;
pons and brainstem;
cerebral cortex and broader forebrain networks;
optic nerve and visual pathways;
auditory pathways.

Secondary systems include skeletal muscle/motor apparatus, spine, eyes, ears, and—depending on phenotype—feeding and respiratory systems. MRI may show pontocerebellar hypoplasia, with cerebellar involvement generally greater than pontine involvement. In the 2017 selected MICPCH cohort, all patients had MRI-confirmed pontocerebellar hypoplasia. (hayashi2017comprehensiveinvestigationof pages 2-3)

Suggested UBERON labels are brain, cerebral cortex, cerebellum, cerebellar granule layer, pons, brainstem, optic nerve, retina, inner ear, and spinal column. No consistent lateralization is established; findings are generally bilateral or diffuse.

8. Temporal development

Onset is congenital or early pediatric. Microcephaly may be prenatal but often becomes more conspicuous postnatally. Developmental delay, hypotonia, hearing loss, or nystagmus may be evident in infancy; seizures can begin in infancy or childhood. (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 8-9)

The course is chronic and lifelong. Head growth deceleration and cerebellar injury may progress, whereas many congenital structural abnormalities remain stable. Experimental post-developmental deletion causes granule-layer atrophy beginning around two months in mice, supporting a continuing requirement for CASK and a degenerative component. (mukherjee2022thenonlinearpath pages 6-8)

No accepted FGS4 staging system, remission pattern, or sharply defined intervention window exists. Early childhood is nonetheless a practical critical period for hearing/vision correction, seizure control, communication support, nutrition, and habilitative therapy.

9. Inheritance and population

Inheritance is X-linked. Hemizygous males are often more severely affected by loss-of-function alleles, while heterozygous females show variable expressivity because of cellular mosaicism from X-inactivation. In the 2023 aggregation, intellectual-disability frequencies were similar by sex, but epilepsy was significantly more common in males. (mori2023diverseclinicalphenotypes pages 5-7)

Many cases are de novo. Recurrence risk is usually low after a proven de novo event but is not zero because parental germline or low-level somatic mosaicism may be missed. In inherited families, a heterozygous mother may transmit the allele to 50% of pregnancies; outcome differs by fetal sex, variant effect, and X-inactivation. Female penetrance and severity are variable rather than predictably complete. Anticipation and consanguinity are not characteristic. (hayashi2017comprehensiveinvestigationof pages 2-3)

No reliable FGS4 prevalence, incidence, carrier frequency, geographic concentration, founder effect, ethnic enrichment, or population sex ratio is available. Referral cohorts are not suitable for population estimation.

10. Diagnostics

Recommended approach

Clinical assessment: developmental history, three-generation pedigree, growth and serial head circumference, neurologic examination, dysmorphology, vision/hearing, feeding, and musculoskeletal examination.
Brain MRI: assess pons, cerebellar hemispheres/vermis, cortex, white matter, ventricles, and optic structures.
EEG for seizures or regression; audiology/ABR and formal ophthalmology regardless of obvious symptoms.
Genetic testing: trio exome or genome sequencing is efficient because of phenotypic and locus heterogeneity. Analysis must include CASK single-nucleotide and indel variants and copy-number calling.
If phenotype strongly indicates CASK disease, use CASK sequencing plus deletion/duplication analysis. Chromosomal microarray is useful for Xp11.4 deletions/duplications but misses most sequence variants.
Confirm variants orthogonally when needed and test parents, including mosaic-sensitive testing where recurrence counseling depends on it.

Karyotyping and FISH have limited resolution and are appropriate mainly for a suspected large rearrangement. Mitochondrial DNA and repeat-expansion testing are not first-line. RNA sequencing can clarify a suspected splice variant or VUS but is not a routine validated diagnostic biomarker. No enzyme assay, blood metabolite, biopsy feature, liquid biopsy, or disease-specific biochemical marker is diagnostic.

Differential diagnosis

MED12-related FG syndrome 1 and other historical FG syndromes;
other pontocerebellar hypoplasias, including TSEN54-related disease;
ITPR1-, RELN-, DYNC1H1-, and DCTN1-related disorders;
other causes of syndromic X-linked intellectual disability, congenital nystagmus, microcephaly, epilepsy, or cerebellar hypoplasia. The 2017 study also identified or considered HDAC2, MARCKS, and HS3ST5 among non-CASK candidates, illustrating MICPCH heterogeneity. (hayashi2017comprehensiveinvestigationof pages 1-2)

No standardized FGS4 clinical diagnostic criteria were found; molecular confirmation is preferred. There is no population or newborn screening program. Cascade testing is appropriate after identifying a familial variant.

11. Outcome and prognosis

FGS4-specific survival curves, mortality rates, and life-expectancy estimates do not exist. Prognosis is highly variable and depends on variant class, sex, mosaicism, brainstem involvement, epilepsy, feeding/respiratory complications, and degree of developmental impairment.

Severe hemizygous null alleles may cause fetal or neonatal death or profound encephalopathy. Brainstem thinning can impair respiratory and swallowing reflexes, increasing risk of central respiratory failure, aspiration, airway infection, and pneumonia. An autopsied male with a p.Arg27Ter allele had a brain approximately 60% of expected weight and an extremely hypoplastic hindbrain. (mukherjee2022thenonlinearpath pages 3-5)

Surviving females and males with hypomorphic or mosaic variants may live into adulthood but commonly require lifelong support. Morbidity includes limited speech and mobility, epilepsy, visual/hearing impairment, scoliosis, feeding difficulties, and dependence in activities of daily living. No validated prognostic biomarker or prediction model exists.

12. Treatment and real-world implementation

There is no approved disease-modifying, gene, RNA, cell, or targeted therapy for FGS4/CASK-related disease. Treatment is individualized and supportive:

antiseizure medication selected by seizure type and EEG;
early physical, occupational, speech/language, feeding, and augmentative-communication therapy;
hearing aids or cochlear evaluation as indicated;
ophthalmologic treatment and visual-access interventions;
nutritional and swallowing assessment, aspiration prevention, and gastrostomy when clinically required;
orthopedic surveillance and treatment of scoliosis/contractures;
management of sleep, constipation, respiratory problems, and behavioral distress;
palliative/supportive planning in severe brainstem disease;
clinical genetics and reproductive counseling.

Suggested NCIt intervention labels include Anticonvulsant Therapy, Physical Therapy, Occupational Therapy, Speech Therapy, Hearing Aid, Gastrostomy, and Genetic Counseling; exact NCIt codes should be terminology-validated before database loading.

No response rates, comparative treatment trials, CASK-specific pharmacogenomic recommendations, or treatment algorithm supported by controlled evidence were found. A search identified no FGS4/CASK-specific interventional trial. Simons Searchlight, NCT01238250, is a recruiting observational genotype-first registry relevant to rare neurodevelopmental disorders; it does not test therapeutic efficacy.

13. Prevention

Primary prevention by lifestyle modification, vaccination, environmental remediation, or medication is not applicable. Secondary and tertiary prevention consist of:

early molecular diagnosis;
seizure recognition and treatment;
hearing and vision screening;
feeding/aspiration, respiratory, and scoliosis surveillance;
early developmental intervention.

After identifying a familial pathogenic variant, reproductive options include prenatal diagnosis and preimplantation genetic testing. Counseling must discuss variable female expression, potentially severe male disease, and residual recurrence risk from parental mosaicism. Population carrier screening and newborn screening are not established.

14. Other species and natural disease

No naturally occurring veterinary disease that is a validated homolog of human FGS4 was identified. CASK is evolutionarily conserved across vertebrates and invertebrates, but experimental ortholog disruption should not be described as naturally occurring FG syndrome. There is no infectious transmission, zoonotic potential, or cross-species contagion.

Relevant experimental taxa include:

Mus musculus—NCBI Taxonomy 10090;
Drosophila melanogaster—7227;
Caenorhabditis elegans—6239.

Exact orthologous NCBI Gene IDs and any OMIA/VBO entries require dedicated database validation.

15. Model organisms and advanced models

Mouse

Constitutive Cask-null mice die within hours of birth, exhibit central respiratory failure, increased thalamic neuronal death, and cleft palate with approximately 80% penetrance. Initial brain lamination and synaptic ultrastructure are comparatively preserved, highlighting limitations of equating early structure with later disease. (mukherjee2022thenonlinearpath pages 5-6, mukherjee2022thenonlinearpath pages 3-5)

Cask+/− female mice express approximately 50% of normal CASK and reproduce major human features: postnatal microcephaly, cerebellar and optic-nerve hypoplasia, scoliosis, impaired coordination, and occasional seizures. They are useful for studying female mosaic disease but show milder behavioral and electrophysiologic phenotypes than many severely affected humans. (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 5-6)

Conditional and cell-specific deletions demonstrate that loss from Purkinje cells or retinal ganglion cells alone is insufficient to cause their death, whereas post-developmental broad deletion eventually causes cerebellar granule-cell degeneration and ataxia. These models support a non-cell-autonomous mechanism and continuing postnatal requirement for CASK. (mukherjee2022thenonlinearpath pages 6-8)

Invertebrates

CASK-null C. elegans show vulval abnormalities through the LET-23/EGF pathway but little neuronal phenotype. Drosophila CASK loss reduces locomotion without major neuromuscular-junction, motor-neuron, or premotor-neuropil abnormalities. These models reveal conserved functions but incompletely recapitulate human hindbrain disease. (mukherjee2022thenonlinearpath pages 3-5)

Cellular and structural models

Co-immunoprecipitation, bimolecular fluorescence complementation, molecular modeling, and patient-variant expression studies show that disease-associated variants can disrupt SAP97, TBR1/CINAP, and neurexin interactions. One study concluded that cooperative PDZ–SH3–GK activity is required for neurexin binding and oligomerization. (pan2021missensemutationsin pages 4-6, pan2021missensemutationsin pages 9-11)

Human fetal brain expresses at least seven CASK transcript variants, four not then represented as known GenBank variants; alternative splicing changes partner affinity, particularly SAP97 binding. This makes transcript choice an important consideration for functional variant assays. (tibbe2021functionalanalysisof pages 1-2)

Recent developments, 2023–2024

The most informative 2023 synthesis quantified sex-stratified manifestations and emphasized domain–phenotype relationships: intellectual disability affected approximately 94–96%, microcephaly/MICPCH 76–88%, and epilepsy 36% of females versus 54% of males in aggregated CASK reports. Its abstract states that CASK disorders are characterized by “MICPCH, epilepsy, congenital nystagmus, and neurodevelopmental disorders.” Published August 2023; DOI: https://doi.org/10.3390/genes14081656. (mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)

A 2024 study, published online in April, used conditional mouse deletion and human variants to show that adult Cask loss can produce progressive cerebellar degeneration and that alternatively spliced vertebrate-specific exons may create region-dependent structural and functional plasticity. DOI: https://doi.org/10.1136/jmg-2023-109747. This advances mechanism and variant interpretation, but it is not yet a therapeutic breakthrough.

Evidence limitations and curation recommendations

Preserve FGS4 as the MONDO entity but attach a strong note that modern evidence is largely CASK-spectrum evidence.
Do not assign MICPCH cohort frequencies directly to FGS4 without an evidence qualifier.
Record variant-level assertions only after transcript-specific ClinVar/HGVS verification.
Mark prevalence, incidence, life expectancy, validated biomarkers, environmental risks/protectors, disease-specific clinical criteria, and controlled treatment outcomes as unknown/not available, rather than zero.
Treat CASK–neurexin, CASK–TBR1/GRIN2B, receptor trafficking, mitochondrial/metabolic stress, and non-cell-autonomous degeneration as complementary hypotheses with different evidence levels—not as one fully proven linear pathway.

Key publications

Mori T, Zhou M, Tabuchi K. Diverse Clinical Phenotypes of CASK-Related Disorders and Multiple Functional Domains of CASK Protein. Genes. Published August 2023. DOI: https://doi.org/10.3390/genes14081656. (mori2023diverseclinicalphenotypes pages 1-2)
Hayashi S, et al. Comprehensive investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual disability and MICPCH. PLOS ONE. Published August 2017. DOI: https://doi.org/10.1371/journal.pone.0181791. (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 2-3)
Pan YE, et al. Missense mutations in CASK…interfere with neurexin binding and neurexin-induced oligomerization. Journal of Neurochemistry. Published May 2021. DOI: https://doi.org/10.1111/jnc.15215. (pan2021missensemutationsin pages 4-6)
Tibbe D, et al. Functional analysis of CASK transcript variants expressed in human brain. PLOS ONE. Published June 2021. DOI: https://doi.org/10.1371/journal.pone.0253223. (tibbe2021functionalanalysisof pages 1-2)
Mukherjee K, LaConte LEW, Srivastava S. The Non-Linear Path from Gene Dysfunction to Genetic Disease: Lessons from the MICPCH Mouse Model. Cells. Published March 2022. DOI: https://doi.org/10.3390/cells11071131. (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 8-9)
Patel PA, et al. Genetic evidence for splicing-dependent structural and functional plasticity in CASK protein. Journal of Medical Genetics. Published April 2024. DOI: https://doi.org/10.1136/jmg-2023-109747.

References

(OpenTargets Search: FG syndrome 4): Open Targets Query (FG syndrome 4, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(mori2023diverseclinicalphenotypes pages 1-2): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.
(hayashi2017comprehensiveinvestigationof pages 1-2): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.
(tibbe2021functionalanalysisof pages 1-2): Debora Tibbe, Yingzhou Edward Pan, Carsten Reißner, Frederike L. Harms, and Hans-Jürgen Kreienkamp. Functional analysis of cask transcript variants expressed in human brain. PLoS ONE, 16:e0253223, Jun 2021. URL: https://doi.org/10.1371/journal.pone.0253223, doi:10.1371/journal.pone.0253223. This article has 16 citations and is from a peer-reviewed journal.
(mukherjee2022thenonlinearpath pages 3-5): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.
(mori2023diverseclinicalphenotypes pages 5-7): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.
(hayashi2017comprehensiveinvestigationof pages 2-3): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.
(mori2023diverseclinicalphenotypes pages 8-9): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.
(martin2025theneurodevelopmentalspectrum pages 1-2): Jessica Martin, Alkistis Mavrogalou-Foti, Josefine Eck, Laura Hattersley, and Kate Baker. The neurodevelopmental spectrum of cask-related disorder. Journal of Neurodevelopmental Disorders, Oct 2025. URL: https://doi.org/10.1186/s11689-025-09643-3, doi:10.1186/s11689-025-09643-3. This article has 6 citations and is from a peer-reviewed journal.
(mukherjee2022thenonlinearpath pages 8-9): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.
(mukherjee2022thenonlinearpath pages 6-8): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.
(pan2021missensemutationsin pages 4-6): Yingzhou Edward Pan, Debora Tibbe, Frederike Leonie Harms, Carsten Reißner, Kerstin Becker, Bri Dingmann, Ghayda Mirzaa, Anja A. Kattentidt‐Mouravieva, Moneef Shoukier, Shagun Aggarwal, Markus Missler, Kerstin Kutsche, and Hans‐Jürgen Kreienkamp. Missense mutations in cask, coding for the calcium‐/calmodulin‐dependent serine protein kinase, interfere with neurexin binding and neurexin‐induced oligomerization. Journal of Neurochemistry, 157:1331-1350, May 2021. URL: https://doi.org/10.1111/jnc.15215, doi:10.1111/jnc.15215. This article has 25 citations and is from a domain leading peer-reviewed journal.
(pan2021missensemutationsin pages 9-11): Yingzhou Edward Pan, Debora Tibbe, Frederike Leonie Harms, Carsten Reißner, Kerstin Becker, Bri Dingmann, Ghayda Mirzaa, Anja A. Kattentidt‐Mouravieva, Moneef Shoukier, Shagun Aggarwal, Markus Missler, Kerstin Kutsche, and Hans‐Jürgen Kreienkamp. Missense mutations in cask, coding for the calcium‐/calmodulin‐dependent serine protein kinase, interfere with neurexin binding and neurexin‐induced oligomerization. Journal of Neurochemistry, 157:1331-1350, May 2021. URL: https://doi.org/10.1111/jnc.15215, doi:10.1111/jnc.15215. This article has 25 citations and is from a domain leading peer-reviewed journal.
(mukherjee2022thenonlinearpath pages 5-6): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.

Artifacts

Edison artifact artifact-00

Domain	FG syndrome 4-specific finding	Broader CASK-spectrum context (clearly labeled)	Suggested ontology/identifier	Evidence caveat
Disease entity	FG syndrome 4 is a rare Mendelian/X-linked neurodevelopmental disorder entity linked to CASK; Open Targets maps FG syndrome 4 to MONDO:0010318 with one associated target, CASK (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: CASK-related disorders include MICPCH, X-linked intellectual disability, epilepsy, congenital nystagmus, hearing impairment, and other neurodevelopmental phenotypes (mori2023diverseclinicalphenotypes pages 1-2)	MONDO:0010318; CASK / ENSG00000147044	Direct FG syndrome 4-specific literature is sparse; much modern interpretation relies on broader CASK-disorder evidence (OpenTargets Search: FG syndrome 4, mori2023diverseclinicalphenotypes pages 1-2)
Causal gene	Historical FGS4 locus was mapped to Xp11.4-p11.3 and is now supported as a CASK-associated entity (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: CASK is an X-chromosomal gene at Xp11.4 encoding a MAGUK-family multidomain scaffold/atypical kinase (hayashi2017comprehensiveinvestigationof pages 1-2, mori2023diverseclinicalphenotypes pages 1-2, tibbe2021functionalanalysisof pages 1-2)	CASK / ENSG00000147044; locus label Xp11.4-p11.3	Gene assignment is strong at disease-platform level, but FGS4 nosology historically overlapped with other FG syndromes (OpenTargets Search: FG syndrome 4)
Inheritance	X-linked inheritance is the best-supported inheritance model for FG syndrome 4 via CASK (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: severe phenotypes often occur in hemizygous males; heterozygous females more commonly survive with variable severity influenced by X-inactivation; many cases are de novo (hayashi2017comprehensiveinvestigationof pages 1-2, mukherjee2022thenonlinearpath pages 3-5, mori2023diverseclinicalphenotypes pages 5-7)	Inheritance label: X-linked	Sex-specific expression and severity are inferred largely from broader CASK cohorts rather than FG syndrome 4-only case series (hayashi2017comprehensiveinvestigationof pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)
Core phenotype	FG syndrome 4 is best understood as a syndromic neurodevelopmental disorder with intellectual/developmental impairment and neurologic abnormalities due to CASK dysfunction (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: intellectual disability in 96.1% of males and 93.5% of females; microcephaly/MICPCH in 76.0% of males and 87.7% of females; epilepsy in 54.1% of males vs 36.1% of females (mori2023diverseclinicalphenotypes pages 5-7)	HPO suggestions: Intellectual disability, Global developmental delay, Microcephaly, Seizure, Nystagmus	These percentages are from aggregated CASK-related disorder reviews, not FG syndrome 4-specific cohorts (mori2023diverseclinicalphenotypes pages 5-7)
Neuroimaging/anatomy	FG syndrome 4 likely belongs within the CASK-linked hindbrain/pontocerebellar phenotype spectrum rather than a purely dysmorphic FG syndrome concept (OpenTargets Search: FG syndrome 4, mori2023diverseclinicalphenotypes pages 1-2)	Broader CASK spectrum: pontocerebellar hypoplasia on MRI is common; in one 41-patient MICPCH cohort, brain MRI confirmed pontocerebellar hypoplasia in all patients studied; progressive microcephaly is characteristic (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 8-9)	UBERON suggestions: cerebellum, pons, brainstem	MRI findings are firmly established for CASK-related MICPCH, but not necessarily reported in every FG syndrome 4-labeled case (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 8-9)
Additional phenotypes	FG syndrome 4 can include ophthalmologic and movement-related manifestations under the CASK-linked phenotype umbrella (OpenTargets Search: FG syndrome 4, mori2023diverseclinicalphenotypes pages 1-2)	Broader CASK spectrum: dystonia, scoliosis, growth retardation, optic atrophy, deafness/hearing loss, hypotonia, and congenital nystagmus are recurrent findings; in a 13-patient series, phenotype included psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, scoliosis, and frequent ophthalmologic anomalies/deafness/epilepsy (hayashi2017comprehensiveinvestigationof pages 2-3, mukherjee2022thenonlinearpath pages 3-5)	HPO suggestions: Hypotonia, Dystonia, Scoliosis, Sensorineural hearing impairment, Optic atrophy	Feature frequencies vary by cohort composition and sex; direct FG syndrome 4 frequency estimates are unavailable (hayashi2017comprehensiveinvestigationof pages 2-3, martin2025theneurodevelopmentalspectrum pages 1-2)
Variant classes	FG syndrome 4 is associated with pathogenic germline CASK variants; altered gene product sequence is the current platform-level consequence annotation (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: nonsense, frameshift, missense, splice, and copy-number variants are all reported; one MICPCH cohort identified 23 point mutations and 9 copy-number variants among 41 patients; all tested parental samples but one were de novo (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)	Variant class labels: missense, frameshift, nonsense, splice-site, copy-number variant	No single recurrent FG syndrome 4 founder variant is established from current retrieved evidence (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 5-7)
Molecular mechanism	FG syndrome 4 is mechanistically attributable to loss or disruption of CASK function in neuronal development and synaptic systems (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: CASK is a multidomain scaffold/atypical kinase with CaMK, L27, PDZ, SH3, and GuK domains; it binds neurexin, liprin-α, SAP97, Tbr1, CINAP and others; disease-associated missense variants can impair neurexin binding/oligomerization and alter transcriptional or receptor-trafficking functions (mukherjee2022thenonlinearpath pages 8-9, mukherjee2022thenonlinearpath pages 6-8, pan2021missensemutationsin pages 4-6, pan2021missensemutationsin pages 9-11, tibbe2021functionalanalysisof pages 1-2)	GO suggestions: synapse organization, protein localization to synapse, regulation of transcription, receptor trafficking	Mechanistic conclusions derive mainly from broader CASK molecular studies rather than FGS4-labeled patient studies (mukherjee2022thenonlinearpath pages 8-9, pan2021missensemutationsin pages 4-6, tibbe2021functionalanalysisof pages 1-2)
Pathophysiology chain	Upstream event: pathogenic CASK variant; intermediate effects: altered scaffolding/protein interactions and neuronal growth regulation; downstream manifestations: developmental delay, microcephaly, pontocerebellar hypoplasia, seizures, visual/oculomotor abnormalities (OpenTargets Search: FG syndrome 4, mori2023diverseclinicalphenotypes pages 1-2)	Broader CASK spectrum: evidence supports non-cell-autonomous postnatal brain growth defects, cerebellar granule-cell vulnerability, altered excitatory/inhibitory balance, and possible metabolic/mitochondrial stress contributions (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 8-9, mukherjee2022thenonlinearpath pages 5-6)	GO suggestions: postnatal brain development, neuron death, synaptic signaling; CL suggestions: cerebellar granule cell, Purkinje cell, retinal ganglion cell	Causal chain remains incompletely resolved; synaptic dysfunction alone may be insufficient to explain degeneration (mukherjee2022thenonlinearpath pages 8-9, mukherjee2022thenonlinearpath pages 6-8)
Diagnosis	Suspect FG syndrome 4 in individuals with X-linked/syndromic neurodevelopmental disorder features and confirm by molecular testing of CASK (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: diagnosis commonly uses exome/genome sequencing or copy-number analysis; CASK screening is especially relevant in microcephaly with pontocerebellar hypoplasia; MRI is supportive; parental testing helps establish de novo status and counseling (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 2-3)	Testing identifiers: CASK sequencing, copy-number analysis, brain MRI	No disease-specific consensus diagnostic criteria for FG syndrome 4 were identified in retrieved evidence (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 2-3)
Differential diagnosis	FG syndrome 4 should be distinguished from other historically named FG syndromes and from other pontocerebellar hypoplasia disorders (OpenTargets Search: FG syndrome 4)	Broader CASK spectrum: differential diagnosis includes other genetic causes of MICPCH/PCH and neurodevelopmental disorders with microcephaly, seizures, or nystagmus; genetic heterogeneity in MICPCH includes non-CASK genes such as ITPR1, RELN, DYNC1H1, DCTN1, HDAC2, MARCKS, HS3ST5 (hayashi2017comprehensiveinvestigationof pages 1-2)	Disease labels: FG syndrome 1 (MED12-related) vs FG syndrome 4 (CASK-related); broader label pontocerebellar hypoplasia	Historical nomenclature can mislead; older FG labels do not always map cleanly to current molecular nosology (OpenTargets Search: FG syndrome 4, hayashi2017comprehensiveinvestigationof pages 1-2)
Treatment/management	No FG syndrome 4-specific disease-modifying therapy was identified in retrieved evidence	Broader CASK spectrum: management is supportive/symptomatic and multidisciplinary, including developmental therapies, seizure management, hearing/vision support, orthopedic monitoring (e.g., scoliosis), nutrition, and genetic counseling; PCH reviews state treatment is still symptomatic (hayashi2017comprehensiveinvestigationof pages 2-3, martin2025theneurodevelopmentalspectrum pages 1-2)	NCIT suggestions by label: Physical Therapy, Occupational Therapy, Speech Therapy, Anticonvulsant Therapy, Genetic Counseling	Management recommendations are inferred from CASK/PCH practice patterns; no controlled FG syndrome 4 treatment trials were found (hayashi2017comprehensiveinvestigationof pages 2-3, martin2025theneurodevelopmentalspectrum pages 1-2)
Prognosis	FG syndrome 4 prognosis is undefined due to rarity and sparse direct follow-up data	Broader CASK spectrum: severity is highly variable; hemizygous males with null variants may be very severe or lethal, whereas heterozygous females can survive with lifelong disability; one cohort showed only 6/41 could walk and 3/41 could speak, underscoring substantial morbidity (hayashi2017comprehensiveinvestigationof pages 2-3, mukherjee2022thenonlinearpath pages 3-5)	Outcome labels: lifelong neurodevelopmental disability, variable severity	No robust disease-specific survival curves, life expectancy estimates, or mortality rates were identified (hayashi2017comprehensiveinvestigationof pages 2-3, mukherjee2022thenonlinearpath pages 3-5)
Epidemiology	No reliable prevalence or incidence estimate for FG syndrome 4 was identified in retrieved evidence	Broader CASK spectrum: disease is rare and likely under-ascertained; published cohorts are small and enriched for severe neurodevelopmental referral populations (hayashi2017comprehensiveinvestigationof pages 1-2, martin2025theneurodevelopmentalspectrum pages 1-2)	MONDO entity: MONDO:0010318	Absence of epidemiologic estimates should be treated as a knowledge gap, not evidence of extreme rarity thresholding (hayashi2017comprehensiveinvestigationof pages 1-2, martin2025theneurodevelopmentalspectrum pages 1-2)
Environment/prevention	No established environmental risk, protective factor, infectious trigger, or gene-environment interaction was identified for FG syndrome 4	Broader CASK spectrum: prevention is primarily genetic/reproductive—family testing when indicated, recurrence-risk counseling, and consideration of prenatal or preimplantation testing after familial variant identification (supported by de novo but occasionally inherited/mosaic contexts) (hayashi2017comprehensiveinvestigationof pages 2-3)	Prevention labels: genetic counseling, prenatal testing (label only)	This is a Mendelian disorder; non-genetic prevention evidence was not found in retrieved sources (hayashi2017comprehensiveinvestigationof pages 2-3)
Clinical trials / real-world implementation	No FG syndrome 4- or CASK-specific interventional therapeutic trial was retrieved	Broader CASK spectrum: a broad observational genotype-first registry, Simons Searchlight (NCT01238250), is recruiting and may capture natural-history/phenotype data across rare neurodevelopmental genetic disorders	NCT01238250	Observational registry participation is not evidence of efficacy for any therapy (OpenTargets Search: FG syndrome 4)
Model organisms	No FG syndrome 4-specific animal model named as such was identified	Broader CASK spectrum: Cask-null mice die within hours of birth; Cask heterozygous females recapitulate microcephaly, cerebellar hypoplasia, optic nerve hypoplasia, scoliosis, and occasional seizures; post-developmental deletion causes cerebellar degeneration and ataxia; Drosophila and C. elegans models show conserved but partial phenotypes (mukherjee2022thenonlinearpath pages 5-6, mukherjee2022thenonlinearpath pages 3-5, mukherjee2022thenonlinearpath pages 6-8)	Model labels: mouse, Drosophila, C. elegans	Models capture major neurodevelopmental aspects but incompletely reproduce human phenotypic breadth and sex-specific mosaic biology (mukherjee2022thenonlinearpath pages 5-6, mukherjee2022thenonlinearpath pages 3-5, mukherjee2022thenonlinearpath pages 6-8)
Recent developments (2023-2024)	For FG syndrome 4 specifically, recent advances mainly come through the broader CASK literature rather than disease-specific series	Broader CASK spectrum: 2023 review quantified sex-stratified phenotype frequencies and domain–phenotype relationships; 2024 work highlighted splicing-dependent structural plasticity and vertebrate-specific exon effects; 2024 reviews summarized broader CASK mechanisms (mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)	Recent-source markers: 2023 review, 2024 mechanistic study	These are important for interpretation, but not direct therapeutic breakthroughs for FG syndrome 4 (mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Variants

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

FG Syndrome 4: Disease Characteristics Research Report

1. Disease information

Definition

Identifiers and synonyms

2. Etiology

Causal factors and genetic risk

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes

4. Genetic and molecular information

Gene and variants

5. Environmental information

6. Mechanism and pathophysiology

Upstream-to-downstream causal model

Important expert interpretation

Ontology suggestions

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Recommended approach

Differential diagnosis

11. Outcome and prognosis

12. Treatment and real-world implementation

13. Prevention

14. Other species and natural disease

15. Model organisms and advanced models

Mouse

Invertebrates

Cellular and structural models

Recent developments, 2023–2024

Evidence limitations and curation recommendations

Key publications

Artifacts